January saw almost every major cardiovascular subspecialty represented among our most-clicked stories of the month.

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the ...

Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

SB5, an adalimumab biosimilar approved in the US, is showing to be safe and effective for patients with psoriasis in the long ...

On January 23, 2025, the District Court for the District of New Jersey entered a Consent Judgment and Injunction in view of a ...

US biotech major Amgen =announced that it has reached resolution of its patent infringement litigation related to South Korea ...

As Sandoz gears up to launch one of the most anticipated biosimilars of the year, the company could face near-term ...